炎症性肠病（IBD）可以被定义为肠道的炎症性疾病，其特征为免疫应答失调和肠道慢性炎症。然而，由于病因和发病机制尚不明确，需要更有效的治疗方法。最近的研究发现了一种新的细胞因子，白细胞介素-27（IL-27），它属于白细胞介素-6和白细胞介素-12超家族，在许多传染性疾病、自身免疫疾病和癌症中发挥多种功能。白细胞介素-27主要由抗原呈递细胞，如树突状细胞和单核巨噬细胞产生，在免疫应答中起到双重调控作用。因此，本文旨在总结白细胞介素-27在IBD中的调控作用的新进展，并更加关注白细胞介素-27与免疫细胞之间的相互作用，希望为白细胞介素-27介导的潜在IBD治疗提供更多证据。© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Inflammatory bowel disease (IBD) can be identified as an inflammatory disorder in the intestine, being characterized by maladjusted immune responses and chronic inflammation of the intestinal tract. However, as the etiology and pathogenesis are still unclear, more effective therapeutic approaches are needed. Recent studies have discovered a new cytokine, interleukin-27 (IL-27), which belongs to the superfamily of IL-6 and IL-12, demonstrating multiple functions in many infectious diseases, autoimmune diseases, and cancers. Interleukin-27 is mainly produced by antigen presentation cells (APCs) such as dendritic cells and mononuclear macrophages, playing a dual regulatory role in immunological response. Therefore, this updated review aims to summarize the new progress of the regulatory role of IL-27 in IBD and focus more on the interaction between IL-27 and immune cells, hoping to provide more evidence for the potential IBD treatment mediated by IL-27.© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.